PriceTargets.com logo

NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$26.35 As of 04/17/2019 01:00 AM ET
+0.30 (1.20%)
Get New Clementia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Clementia Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $26.35.
N/A
The current consensus among 0 investment analysts is to n/a stock in Clementia Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2019Robert W. BairdDowngradeOutperform ➝ Neutral$27.00Low
i
2/26/2019Bloom BurtonDowngradeBuy ➝ HoldLow
i
Rating by D. Martin at Bloom Burton
2/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$26.00Medium
i
Rating by J. Schwartz at SVB Leerink LLC
2/25/2019WedbushDowngradeOutperform ➝ NeutralLow
i
Rating by D. Nierengarten at Wedbush
1/18/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$24.00Medium
i
12/16/2018Bloom BurtonReiterated RatingBuyLow
i
Rating by D. Martin at Bloom Burton
8/15/2018B. RileyLower Price TargetBuy ➝ Buy$25.00 ➝ $16.00High
i
Rating by M. Kumar at B. Riley
8/13/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$27.00 ➝ $26.00Low
i
8/10/2018WedbushReiterated RatingOutperform$26.00Low
i
3/28/2018B. RileyInitiated CoverageBuy$25.00Medium
i
Rating by M. Kumar at B. Riley
11/14/2017WedbushReiterated RatingOutperform$26.00N/A
i
Rating by D. Nierengarten at Wedbush
8/31/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$32.00Low
i
8/28/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$23.00High
i
Rating by J. Schwartz at SVB Leerink LLC
8/28/2017WedbushInitiated CoverageOutperform ➝ Outperform$26.00 ➝ $26.00High
i
Rating by D. Nierengarten at Wedbush
8/28/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$27.00High
i
(Data available from 4/14/2016 forward)
Clementia Pharmaceuticals logo
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Read More

Today's Range

Now: $26.35
$26.28
$26.69

50 Day Range

MA: $26.35
$26.35
$26.35

52 Week Range

Now: $26.35
$8.10
$26.73

Volume

716,706 shs

Average Volume

145,059 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Clementia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Clementia Pharmaceuticals in the last twelve months:
View the latest analyst ratings for CMTA.

What is the current price target for Clementia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Clementia Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Clementia Pharmaceuticals in the next year.
View the latest price targets for CMTA.

What is the current consensus analyst rating for Clementia Pharmaceuticals?

Clementia Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CMTA.

What other companies compete with Clementia Pharmaceuticals?

Other companies that are similar to Clementia Pharmaceuticals include Arena Pharmaceuticals, Hypera, Emergent BioSolutions, Turning Point Therapeutics, Agios Pharmaceuticals, I-Mab, Legend Biotech, Nektar Therapeutics, Apellis Pharmaceuticals, PTC Therapeutics, ACADIA Pharmaceuticals, ChemoCentryx, Insmed, InnovAge and Reata Pharmaceuticals.

How do I contact Clementia Pharmaceuticals' investor relations team?

Clementia Pharmaceuticals' physical mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company's listed phone number is 514-940-3600 and its investor relations email address is [email protected] The official website for Clementia Pharmaceuticals is www.clementiapharma.com.